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Abstract
In 2014, the nomenclature of bisphosphonate-related osteonecrosis of the jaw (BRONJ) 
was changed in medication-related osteonecrosis of the jaw (MRONJ) to include 
osteonecrosis of the jaw caused by non-bisphosphonates (BPs) drugs. MRONJs are a 
rare drug adverse reaction associated with BPs and other antiresorptive (denosumab) 
and antiangiogenetic therapies. MRONJ pathophysiology is not completely elucidated, 
and three risk factors should be considered: Local factors, underlying disease and kind 
of medication. MRONJ aﬀ ects considerably patient’s quality of life, so it is important 
to know pathology and risk factor in order to prevent or treat immediately the disease. 
Various BRONJ staging systems are used by clinicians: In 2006 Ruggero at al. proposed 
a clinical staging system with three diﬀ erent levels based on signs and symthoms; in 2009 
American Association of Oral and Maxillofacial Surgeons implemented it with Stage 0. 
Marx in 2007 was the only one who divided the stages on the basis of the lesion’s size. 
Bedogni in 2012 proposed a clinical-radiological staging system. The aim of this review 
is to summarize the current diagnosis, prevention and treatment strategies.
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Introduction
In 2014, the American Association of Oral and Maxillofacial 
Surgeons (AAOMS) changed the nomenclature of 
bisphosphonate-related osteonecrosis of the jaw (BRONJ) 
into medication-related osteonecrosis of the jaw (MRONJ), 
to accommodate the growing number of osteonecrosis 
cases involving the maxilla and mandible associated with 
other antiresorptive (denosumab) and antiangiogenetic 
therapies.[1] MRONJ aﬀ ects considerably patient’s quality of life, 
so it’s important to know pathology and risk factor in order to 
prevent or treat immediately the disease. The aim of this review is 
to represent the current knowledge about MRONJ: Prevention, 
diagnosis and treatment strategies.
Related Medications and Risk Factors
Two pharmacological agents are involved in the ONJ process: 
Both antiresorptive (Bisphosphonates [BPs] and RANK-L 
inhibitors) and antiangiogenetic drugs (Table 1, Table 2).
Antiresorptive
BPs can be classifi ed into aminobisphosphonates (NBPs) and 
non-aminobisphosphonates (non-NBPs) on the basis of an 
amino functional group presence, NBPs are the one involved in 
the osteonecrosis of the jaw.
NBPs can be administrated orally or as intravenous (IV) drugs:
• IV BPs are used in the management of cancer-related 
conditions, including hypercalcemia of malignancy, skeletal-
related events associated with bone metastases of solid tumor 
such as breast cancer, prostate cancer, and lung cancer and 
for multiple myeloma.[2-14]
• Oral BPs are prescribed for osteoporosis,[15,16] osteopenia[17] 
or other less common conditions (Paget’s disease and 
osteogenesis imperfect).[18,19]
• RANK ligand inhibitor (denosumab) is an antiresorptive 
medication used in patients affected by osteoporosis 
or metastatic bone disease, which inhibits osteoclast 
function, decreases bone resorption and increases bone 
density.[20,21]
Antiangiogenetic
A class of drugs, which interferes with the formation of new 
blood vessels, is blocking the angiogenesis signaling cascade.
Monoclonal antibodies stop receptor or growth factor 
(bevacizumab) while small molecules determine the block by 
binding the tyrosine kinase receptor (Sunitinib and Sorafenib), 
facilitating the other anticancer agents delivery.[22]
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microtrauma, altereted bone remodeling, or oversuppression 
of bone resorption, angiogenesis inhibition, soft tissue 
BPs toxicity, a peculiar biofilm of the oral cavity, terminal 
vascularization of the mandible, suppression of immunity or 
Vitamin D deficiency.[23,27-36]
Three risk factors should be considered: Local factors, 
underlying disease and kind of medication.
Age, sex, use of alcohol and tobacco are all individual risk 
factors that may be associated with other systemic factors or 
concurrent pathologies such as diabetes, rheumatoid arthritis, 
dialysis, anemia, hypocalcemia, immunosuppression, and 
osteomalacia. Local risk factors include microtrauma, oral surgery, 
removable prosthesis, anatomic conditions such as tori and oral 
implantology. Medication-related risk factors, which should be 
considered, are the molecule, the way of administration and 
the length of therapy. To explain disease frequency, we have to 
consider two criterions: Therapeutic indications (osteoporosis/
osteopenia and malignancy) and type of medication (BP and 
non-BP). Exposition to zolendronate in cancer patients leads to 
ONJ risk 50-100 times higher than cancer patients treated with 
placebo. Even if the ONJ risk is similar in patients treated by 
denosumab, it’s important to underline a substantial diﬀ erence 
between BRONJ and denosumab-related osteonecrosis of the 
jaw (DRONJ). BRONJ occurs after a mean administration 
of 33 months (IV in cancer patients) or 48 months (OS in 
osteporotic patients). DRONJ occurs early after treatment, 
independently of the number of previous administrations. 
Hence, ONJ risk after use of RANK-L inhibitors decreases 
monthly, while for bisphosphonate drugs remains stable for 
years. The risk of BRONJ is directly related to the duration of 
the therapy and total amount of the medications.[37-39]
MRONJ pathophysiology is not completely 
elucidated.[23-26] Its unique localization to the jaws may be 
explained by several hypothesis: Inflammation or infection, 
Table 1: MRONJ related medications
Molecule Category Indication
Alendronate Bisphosphonate Osteoporosis
Risedronate Bisphosphonate Osteoporosis
Ibandronate Bisphosphonate Osteoporosis
Neridronate Bisphosphonate Osteogenesis imperfect
Paget’s disease of bone
Pamidronate Bisphosphonate Bone metastases
Zolendronate Bisphosphonate Bone metastases
Osteoporosis
Tiludronate Bisphosphonate Paget’s disease of bone
Denosumab RANK-L inhibitors Bone metastases
Osteoporosis
Sunitib Tyrosine kinase 
inhibitors
GIST, RCC, pNET
Sorafenib Tyrosine kinase 
inhibitors
HCC, RCC
Bevacizumab Humanized 
monoclonal antibody
mCRC, NSCLC, Glio, 
mRCC
Sirolimus Mammalian target of 
rapamycin pathway
Organ rejection in renal 
transplant
GIST: Gastrointestinal stromal tumor, RCC: Renal cell carcinoma; 
pNET: Pancreatic neuroendocrine tumor, HCC: Hepatocellular carcinoma, 
mCRC: Metastatic colorectal carcinoma, NSCLC: Non-squamous 
non-small cell lung carcinoma, Glio: Glioblastoma, mRCC: Metastatic renal 
cell carcinoma, MRONJ: Medication-related osteonecrosis of the jaw
(Cond..)
Stage Marx 2007[49] Ruggiero et al.[2] Bedogni[36]
At risk 
category
No apparent exposed/
necrotic bone in patients who 
have been treated with either 
oral or IV bisphosphonates
Stage 0 Subclinical damage, 
microscopically represented 
by beginner hypocellularity 
osteoclast apoptosis and 
decrease of endosteal osteoblast
Nonspecifi c clinical fi ndings 
and symptoms such as 
jawpain or osteosclerosis 
but no clinical evidence of 
exposed bone
Stage 1 A: Painless exposed bone 
<1 cm
B: Painless exposed bone 
>1 cm
Exposed/necrotic bone 
in patients who are 
asymptomatic and who 
have no evidence of 
infection
Focal BRONJ
Clinical signs and symptoms: bone exposure; sudden dental 
mobility; nonhealing postextraction socket; mucosal fi stula; 
swelling; abscess formation; trismus; gross mandibular 
deformity; and/or hypoesthesia/paraesthesia of the lips
CT fi nding: increased bone density limited to the alveolar bone 
region (trabecular thickening and/or focal osteosclerosis), 
with or without the following signs: markedly thickened and 
sclerotic lamina dura; persisting alveolar socket; and/or cortical 
disruption:
1a: Asymptomatic
1b: Symptomatic (pain and purulent discharge)
Table 2: Diff erent BRONJ staging systems
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Table 3: Prevention strategies
Cancer patients before starting 
IV medical treatment
Asymptomatic cancer 
patients receiving IV 
medical treatment
Osteoporotic patients 
before starting oral 
medical treatment
Osteoporotic patients receiving oral medical 
treatment
Inadequate dentures should be 
modifi ed, rebased or replaced. 
Patients should achieve a 
proper oral hygiene and be 
instructed to report any pain, 
swelling or exposed bone. If 
allowed by systemic conditions, 
initiation of antiresorptive 
or antiangiogenetic therapy 
should be delayed until oral 
health is stable or, at least, 
until the extraction site has 
mucosalized (2-3 weeks) or 
until an adequate osseous 
healing
A good oral hygiene is 
essential to prevent dental 
infections that may require 
dentoalveolar surgery. 
Indeed, every invasive 
procedure that involves 
bone injury should be 
avoided. Non-restorable 
teeth should be treated 
by removal of the crown 
and endodontic treatment 
of the remaining roots. 
Dental implants placement 
should be avoided
Starting treatment, 
patients should be 
educated to the risk 
of MRONJ. Th e 
importance of oral 
hygiene and dental 
health should be 
underlined
(1)  Patients treated with oral-NBP for less than 
4 years without risk factors
No modifi cation or delay of surgery is necessary
(2)  Patients treated with oral-NBP for less than 
4 years and corticosteroids or antiangiogenetic 
drugs concurrently
Th e prescriber should be contacted to evaluate 
a drug holiday for at least 2 months before oral 
surgery
(3)  Patients treated with oral-NBP for more than 
4 years
Th e prescriber should be contacted to evaluate 
a drug holiday for at least 2 months before oral 
surgery
IV: Intravenous
Defi nition and Staging Systems
According to the last defi nition by AAOMS in 2014, Patients are 
aﬀ ected by MRONJ if all the following clinical manifestations are 
demonstrated:
1. Current or previous therapy with antiresorptive or 
antiangiogenetic drugs;[2]
2. No patient history of radiation therapy or manifest metastatic 
disease to the jaw;
3. Exposed bone or presence of an intraoral or extraoral fi stula 
in the maxillofacial region persisting for more than 8 weeks.
However, there is no unanimous consensus on point three, 
because the exposed necrotic bone in the oral cavity is just one 
of the possible manifestations of BRONJ and it is not found in 
all patients.
In 2012, the Italian Society for Maxillofacial Surgery and the 
Italian Society of Oral Pathology and Medicine proposed a new 
defi nition:[37] “BRONJ is an adverse drug reaction described as 
the progressive destruction and death of bone that aﬀ ects the 
mandible or maxilla of patients exposed to the treatment with 
nitrogen-containing BPs, in the absence of a previous radiation 
treatment.” Only 76% of BRONJ were diagnosed based on 
the AAOMS defi nition: Up to a quarter of patients with 
osteonecrosis of the jaw associated with antiresorptive agents 
remain undiagnosed.
Various BRONJ staging systems are used by clinicians: In 
2006 Ruggero et al.[33] proposed a clinical staging system with 
three diﬀ erent levels based on signs and symthoms; in 2009, 
AAOMS implemented it with Stage 0.[2] Marx[35] in 2007 was the 
Stage Marx 2007[49] Ruggiero et al.[2] Bedogni[36]
Stage 2 A: Painful and infected single 
exposed bone <2 cm
B: Painful and infected single 
exposed bone >2 cm
Exposed/necrotic bone 
associated with infection 
as evidenced by pain and 
erythema in the region of 
the exposed bone with or 
without purulent drainage
Diff use BRONJ
Clinical signs and symptoms: the same as Stage 1
CT fi ndings: increased bone density extended to the basal 
bone (diff use osteosclerosis), with or without the following 
signs: prominence of the inferior alveolar nerve canal; periosteal 
reaction; sinusitis; sequestra formation; and/or oroantral fi stula:
1a: Asymptomatic
1b: Symptomatic (pain and purulent discharge)
Stage 3 A: Multiple exposed bone 
areas without clinical fi ndings 
of osteolysis, orocutaneous 
fi stula, or pathological 
fractures
B: Exposed bone >3 cm 
or with clinical fi ndings of 
osteolysis, or orocutaneous 
fi stula, or pathological 
fractures
Exposed/necrotic bone 
in patients with pain, 
infection, and one or more 
of the following: pathologic 
fracture, extraoral fi stula, 
or osteolysis extending to 
the inferior border or sinus 
fl oor
Complicated BRONJ
Th e same as Stage 2, with one or more of the following: clinical 
signs and symptoms: extraoral fi stula; displaced mandibular 
stumps; nasal leakage of fl uids
CT fi ndings: Osteosclerosis of adjacent bones (zygoma, hard 
palate); pathologic mandibular fracture; and/or osteolysis 
extending to the sinus fl oor
BRONJ: Bisphosphonate-related osteonecrosis of the jaw, AAOMS: American Association of Oral and Maxillofacial Surgeons, SICMF: Italian Society for 
Maxillofacial Surgery, SIPMO: Italian Society of Oral Pathology and Medicine, IV: Intravenous, CT: Computed tomography
Table 2: (Continued...)
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Patients about to start IV 
medical treatment
Patients receiving IV medical 
treatment
Patients receiving oral NBPs by 
less than 4 years
Patients receiving oral NBPs by more 
than 4 years
Oral health examination
Clinical examination
Radiological examination
General and oral health 
record
Follow-up program with regular 
check-ups every 4-6 months
Orthopantomography every 
6-12 months
Dental cone beam CT if the 
orthopantomography is uncertain
Follow-up program with regular 
check-ups every 6 months
Orthopantomography just in case 
of MRONJ signs and symptoms
Dental cone beam CT if the 
orthopantomography is uncertain
Follow-up program with regular visits 
once every 4-6 months
Orthopantomogram just in case of 
MRONJ signs and symptoms
Dental cone beam CT if the 
orthopantomography is uncertain
Oral health achievement/
conservation
Extraction of partial 
embedded teeth or those 
with poor prognosis
Extraction of mobile 
deciduous teeth in children
Periodontal stabilization 
splints for teeth with a grade 
1-2 mobility in patients 
with a good dental hygiene; 
extraction in patients with a 
poor dental hygiene
Conservative, endodontic 
and prosthodontics therapy 
of teeth with good prognosis
Mandibular or maxillary 
tori removal, especially if 
multilobate and/or with 
great dimensions
Adjust, rebase or replace 
inadequate removable 
denture to decrease the 
oral tissue pressure and to 
prevent sore spots, especially 
along the lingual fl ange 
region or at the tori
Local risk factors elimination 
(i.e. inadequate conservative 
or prosthodontics 
restorations)
Endodontic procedures should be 
preferred to dental surgery
Endodontic procedures should be 
completed without any osseous 
injury
Every conventional procedure 
of restorative dentistry or 
prosthodontics could be completed
Local fl uoride administration
Scaling and root planning
Periodontal stabilization splints 
for teeth with a grade 1-2 mobility 
in patients with a good dental 
hygiene; extraction in patients with 
a poor dental hygiene
It should be carefully assess 
the possibility of a GBR/GTR 
procedure due to an antiangiogenic 
eff ect of NBP therapy
In case of implantology, the patient 
should be informed about the 
possibility of long-term MRONJ
Endodontic procedures should be 
preferred to dental surgery
Endodontic procedures should be 
completed without any osseous 
injury
Every conventional procedure 
of restorative dentistry or 
prosthodontics could be 
completed
Local fl uoride administration
Scaling and root planning
Periodontal stabilization 
splints for teeth with a grade 
1-2 mobility in patients with a 
good dental hygiene; extraction 
in patients with a poor dental 
hygiene
It should be carefully assess 
the possibility of a GBR/
GTR procedure due to an 
antiangiogenic eff ect of NBP 
therapy
In case of implantology, the 
patient should be informed about 
the possibility of a long-term 
MRONJ
Extraction of teeth with 
a grade 3 mobility and/or 
endodontal-periodontal lesions
Endodontic procedures should be 
preferred to dental surgery
Endodontic procedures should be 
completed without any osseous injury
Every conventional procedure of 
restorative dentistry or prosthodontics 
could be completed
Local fl uoride administration
Risk factors elimination
Scaling and root planning
Periodontal stabilization splints for 
teeth with a grade 1-2 mobility without 
endodontic/periodontal lesions
Implant placement is possible but the 
patient should be informed about the 
possibility of a short and long term 
MRONJ
Avoid using anesthesia with 
vasoconstrictor agents
Extraction of teeth with a grade 3 
mobility and/or endodontal-periodontal 
lesions is indicated. Aft er an antibiotic 
prophylaxis, the surgical procedure 
should be executed with the lowes 
possible bone injury. All the granulation 
tissue should be removed and a primary 
closure is necessary
Adequate oral hygiene 
achievement
Scaling and root planning
Chlorhexidine 0.12% oral 
rinse (7 days/month)
Oral hygiene instruction 
and motivation
Chlorhexidine 0.12% oral rinse 
(60 s/2 times a day for 7 days/
month)
Risk factors elimination
Adjust, rebase or replace 
inadequate removable denture to 
decrease the oral tissue pressure 
and to prevent sore spots, 
especially along the lingual fl ange 
region or at the tori
Chlorhexidine 0.12% oral rinse 
(60 s/2 times a day for 7 days/
month)
Risk factors elimination
Adjust, rebase or replace 
inadequate removable denture to 
decrease the oral tissue pressure 
and to prevent sore spots, 
especially along the lingual fl ange 
region or at the tori
Chlorhexidine 0.12% oral rinse 
(60 s/2 times a day for 7 days/month)
Adjust, rebase or replace inadequate 
removable denture to decrease the oral 
tissue pressure and to prevent sore spots, 
especially along the lingual fl ange region 
or at the tori
In case of fi xed prosthodontics, the 
biological width should be respected
Medical treatment 
management
Table 4: Treatment strategies
(Cond..)
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only one who divided the stages on the basis of the lesion’s size. 
Bedogni et al.[37] in 2012 proposed a clinical-radiological staging 
system.
Prevention of MRONJ
Dental screenings and adequate treatment are fundamental in 
order to reduce ONJ risk in patients under antiresorptive or 
antiangiogenetic therapy, or before starting the administration 
[Table 3].
The risk of ONJ increases when the duration of therapy 
exceeded 4 years. However, the risk of MRONJ in patients 
treated with oral BPs is lower compared to subjects treated with 
IV medications.
Conclusions
Treatment of ONJs is a demanding challenge for clinicians 
and an eﬀ ective and appropriate MRONJ therapy is still to be 
decided, its strategies are described in Table 4.
The choice between a conservative treatment and surgery is 
not easy, and it should be made on a case by case basis. However, 
the initial approach should be as conservative as possible .
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